

**UNITED STATES SECURITIES AND EXCHANGE  
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Blouse Grant E.</u>  (Last) (First) (Middle) C/O CATALYST BIOSCIENCES, INC. 611 GATEWAY BOULEVARD, SUITE 710  (Street) SOUTH SAN FRANCISCO CA 94080  (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> 07/12/2021	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>CATALYST BIOSCIENCES, INC. [ CBIO ]</u>	
		<b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Scientific Officer	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,754 <sup>(1)</sup>	D	

**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(2)	07/16/2028	Common Stock	30,000	12.21	D	
Stock Option (Right to Buy)	(3)	07/30/2028	Common Stock	10,000	9.68	D	
Stock Option (Right to Buy)	(4)	01/24/2029	Common Stock	18,000	7.97	D	
Stock Option (Right to Buy)	(5)	01/23/2029	Common Stock	35,000	6.85	D	
Stock Option (Right to Buy)	(6)	02/08/2031	Common Stock	38,500	5.89	D	
Stock Option (Right to Buy)	(7)	06/16/2031	Common Stock	25,000	4.33	D	

**Explanation of Responses:**

- Includes shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on various dates between February 11, 2019 and February 9, 2021.
- 25% of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of July 2, 2018, and 1/48 of the shares subject to the option vested or will vest on each monthly anniversary of the vesting commencement date thereafter.
- 25% of the shares subject to the option vested on the one-year anniversary of the vesting commencement date of July 1, 2018, and 1/48 of the shares subject to the option vested or will vest on each monthly anniversary of the vesting commencement date thereafter.
- The option vested or will vest over a four (4) year period on each monthly anniversary of the vesting commencement date of January 24, 2019.
- The option vested or will vest over a four (4) year period on each monthly anniversary of the vesting commencement date of January 23, 2020.
- 25% of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date of February 8, 2021, and 1/48 of the shares subject to the option will vest on each monthly anniversary of the vesting commencement date thereafter.
- 25% of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date of June 16, 2021, and 1/48 of the shares subject to the option will vest on each monthly anniversary of the vesting commencement date thereafter.

**Remarks:**

/s/ Faisal Shawwa  
 Attorney-in-Fact for Grant 07/15/2021  
 E. Blouse

\*\* Signature of Reporting

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

The undersigned as a Section 16 reporting person of Catalyst Biosciences, Inc. (the "Company"), hereby constitutes and appoints each of Nassim Usman, Clinton J. Musil and Faisal Shawwa, signing singly, as the undersigned's true and lawful attorney-in-fact to:

1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of the Company, Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;

2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the U.S. Securities and Exchange Commission and any securities exchange or similar authority; and

3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to the attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned also ratifies hereby any action previously taken by the attorney-in-fact that would have been authorized by this power of attorney if it has been in effect at the time such action was taken. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 21st day of June, 2021.

/s/ Grant E. Blouse  
Name: Grant E. Blouse